BYSIのチャート
BYSIの企業情報
| symbol | BYSI |
|---|---|
| 会社名 | BeyondSpring Inc （ビヨンドスプリング） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product Plinabulin into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe grade 4 neutropenia and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent which induces T-cell activation. The Company's IkappaB kinase (IKK) program BPI-003 is based on a small molecule inhibitor of IKK a protein kinase. ビヨンドスプリングは米国のバイオ医薬品メ―カ―。末期の免疫性腫瘍の治療薬も含む、革新的ながん治療薬の開発に注力する。主要製品候補の「プリナブリン」は、進行性非小細胞肺がんの治療薬及び好中球減少症の予防薬として臨床段階中である。また、モノクロ―ナル抗体医薬品のニボルマブとプリナブリンを組み合わせた治療薬も開発中。本社はニューヨーク。 BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City. |
| 本社所在地 | 28 Liberty Street 39th Floor New York NY 10005 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 646-528-4184 |
| 設立年月日 | 41944 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 38人 |
| url | www.beyondspringpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bysi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -64.95400 |
| 終値（lastsale） | 23.5345 |
| 時価総額（marketcap） | 528013028.719 |
| 時価総額 | 時価総額（百万ドル） 529.95460 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 508.41660 |
| 当期純利益 | 当期純利益（百万ドル） -58.02300 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 March 2018 Beyondspring Inc revenues was not reported. Net loss decreased 71% to $13.7M. Lower net loss reflects Research_Development decrease of 70% to $14.1M (expense) General and administrative decrease of 30% to $728K (expense) Foreign Exchange Gain Net increase from $74K to $332K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.01 to -$0.77. |
BYSIのテクニカル分析
BYSIのニュース
How should investors view BeyondSpring Inc. (BYSI)? 2023/02/07 15:00:00 US Post News
BeyondSpring Inc. (NASDAQ:BYSI) marked $3.05 per share on Monday, up from a previous closing price of $2.70. While BeyondSpring Inc. has overperformed by 12.96%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BYSI rose by 2.01%, with highs and lows ranging from $3.32 to $0.54, whereas […]
Current Stock in Action: Bilibili Inc. (NASDAQ:BILI 4.28%), BeyondSpring Inc. (NASDAQ:BYSI -2.63%) 2023/01/26 17:06:10 Stock Equity
BILI has seen its SMA50 which is now 24.09%. In looking the SMA 200 we see that the stock has seen a 27.70%. BYSI has seen its SMA50 which is … The post Current Stock in Action: Bilibili Inc. (NASDAQ:BILI 4.28%), BeyondSpring Inc. (NASDAQ:BYSI -2.63%) appeared first on Stocks Equity .
How did BeyondSpring Inc. (BYSI) fare last session? 2023/01/25 12:48:00 US Post News
As of Tuesday, BeyondSpring Inc.’s (NASDAQ:BYSI) stock closed at $2.67, down from $2.72 the previous day. While BeyondSpring Inc. has underperformed by -1.84%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BYSI fell by -18.60%, with highs and lows ranging from $3.49 to $0.54, whereas the […]
Hypnotizing stocks: Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), BeyondSpring Inc. (NASDAQ:BYSI) 2023/01/10 23:11:27 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Hypnotizing stocks: Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), BeyondSpring Inc. (NASDAQ:BYSI) appeared first on Stocks Equity .
BeyondSpring Inc. PT Lowered to $1 at BofA Securities 2023/01/05 11:21:06 Investing.com
https://www.investing.com/news/pro/beyondspring-inc-pt-lowered-to-1-at-bofa-securities-432SI-2973771
BeyondSpring Inc. PT Lowered to $1 at BofA Securities 2023/01/05 11:21:06 Investing.com
https://www.investing.com/news/pro/beyondspring-inc-pt-lowered-to-1-at-bofa-securities-432SI-2973771
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday''s Mid-Day Session 2022/12/21 18:51:35 Benzinga
Gainers Sintx Technologies, Inc. (NASDAQ: SINT ) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical machining. Venus Concept Inc. (NASDAQ: VERO ) gained 63.3% to $0.4122 after the company announced it received a 510(k) clearance from the FDAto market its AI.ME next generation robotic technology for fractional skin resurfacing. Laser Photonics Corporation (NASDAQ: LASE ) jumped 40% to $2.1499 after the company announced it received an order from the largest glass manufacturer in North America. Cenntro Electric Group Limited (NASDAQ: CENN ) rose 33.6% to $0.3561. Cenntro started shipments of LS260 and LS100 vans to European Markets. F-star Therapeutics, Inc. (NASDAQ: FSTX ) gained 29.9% to $5.59. Rekor Systems, Inc. (NASDAQ: REKR ) jumped 28% to $0.7622. Rekor announced financing to solidify cash position and accelerate business growth and technology development. Mobile Global Esports Inc. (NASDAQ: MGAM ) jumped 25% to $0.7885.
BeyondSpring, Exact Sciences top healthcare gainers; Synaptogenix, BiondVax among losers 2022/12/16 15:06:02 Seeking Alpha
BeyondSpring (BYSI) +46%. Exact Sciences (EXAS) +24%. Synaptogenix (SNPX) -69%. BiondVax Pharmaceuticals BVXV -57%.
BeyondSpring Inc. (NASDAQ: BYSI) Jumps 35.94%, Turning Investors Away 2022/12/14 14:00:00 Stocks Register
BeyondSpring Inc. (NASDAQ:BYSI) traded at $1.03 at close of the session on Tuesday, 12/13/22, made an upward move of 35.94% on its previous day’s price. Looking at the stock we see that its previous close was $0.76 and the beta (5Y monthly) reads 1.11 with the day’s price range being $0.88 – $1.20. In terms … BeyondSpring Inc. (NASDAQ: BYSI) Jumps 35.94%, Turning Investors Away Read More »
Why Are BeyondSpring Shares Trading Higher? 2022/12/13 19:57:48 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) presented data from the lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients. In summary, data from 101 and 103 studies, plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN, and duration of severe neutropenia (DSN) compared to the control. There was a reduction in mean … Full story available on Benzinga.com
After A 40.71% Jump In The Last Week, Does BeyondSpring Inc. (NASDAQ: BYSI) Still Make Sense To Buy? 2022/06/04 16:00:00 Marketing Sentinel
During the last session, BeyondSpring Inc. (NASDAQ:BYSI)’s traded shares were 0.39 million, with the beta value of the company hitting 1.24. At the end of the trading day, the stock’s price was $1.59, reflecting an intraday gain of 16.06% or $0.22. The 52-week high for the BYSI share is $33.00, that puts it down -1975.47 … After A 40.71% Jump In The Last Week, Does BeyondSpring Inc. (NASDAQ: BYSI) Still Make Sense To Buy? Read More »
During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect 2022/04/23 18:00:00 Marketing Sentinel
During the last session, BeyondSpring Inc. (NASDAQ:BYSI)’s traded shares were 0.32 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $1.95, reflecting an intraday gain of 3.72% or $0.07. The 52-week high for the BYSI share is $33.00, that puts it down -1592.31 … During The Past Six Months, BeyondSpring Inc. (NASDAQ: BYSI) Shares Took An -88.09% Jump. Here Is What We Should Expect Read More »
Li Auto, Luckin Coffee and BeyondSpring headline a SEC watch list for accounting compliance 2022/04/21 19:33:16 Seeking Alpha
The SEC added 17 more firms to the Holding Foreign Companies Accountable Act list of companies. Read more about the watch list.
BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2021 Results - Earnings Call Transcript 2022/04/14 17:06:06 Seeking Alpha
BeyondSpring Inc. (NASDAQ:NASDAQ:BYSI) Q4 2022 Earnings Conference Call April 14, 2022, 08:00 AM ET Company Participants Ashley Sierchio - LifeSci Advisors Lan Huang - Co-Founder, Chairman…